Cargando…

Treatment of dogs with fluralaner reduced pyrethroid-resistant Triatoma infestans abundance, Trypanosoma cruzi infection and human-triatomine contact in the Argentine Chaco

BACKGROUND: Triatomine elimination efforts and the interruption of domestic transmission of Trypanosoma cruzi are hampered by pyrethroid resistance. Fluralaner, a long-lasting ectoparasiticide administered to dogs, substantially reduced site infestation and abundance of pyrethroid-resistant Triatoma...

Descripción completa

Detalles Bibliográficos
Autores principales: Gürtler, Ricardo Esteban, Laiño, Mariano Alberto, Alvedro, Alejandra, Enriquez, Gustavo Fabián, Macchiaverna, Natalia Paula, Gaspe, María Sol, Cardinal, Marta Victoria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9277862/
https://www.ncbi.nlm.nih.gov/pubmed/35831874
http://dx.doi.org/10.1186/s13071-022-05343-2
_version_ 1784746072903516160
author Gürtler, Ricardo Esteban
Laiño, Mariano Alberto
Alvedro, Alejandra
Enriquez, Gustavo Fabián
Macchiaverna, Natalia Paula
Gaspe, María Sol
Cardinal, Marta Victoria
author_facet Gürtler, Ricardo Esteban
Laiño, Mariano Alberto
Alvedro, Alejandra
Enriquez, Gustavo Fabián
Macchiaverna, Natalia Paula
Gaspe, María Sol
Cardinal, Marta Victoria
author_sort Gürtler, Ricardo Esteban
collection PubMed
description BACKGROUND: Triatomine elimination efforts and the interruption of domestic transmission of Trypanosoma cruzi are hampered by pyrethroid resistance. Fluralaner, a long-lasting ectoparasiticide administered to dogs, substantially reduced site infestation and abundance of pyrethroid-resistant Triatoma infestans Klug (Heteroptera: Reduviidae) in an ongoing 10-month trial in Castelli (Chaco Province, Argentina). We assessed the effects of fluralaner on vector infection with T. cruzi and blood meal sources stratified by ecotope and quantified its medium-term effects on site infestation and triatomine abundance. METHODS: We conducted a placebo-controlled, before-and-after efficacy trial of fluralaner in 28 infested sites over a 22-month period. All dogs received either an oral dose of fluralaner (treated group) or placebo (control group) at 0 month post-treatment [MPT]. Placebo-treated dogs were rescue-treated with fluralaner at 1 MPT, as were all eligible dogs at 7 MPT. Site-level infestation and abundance were periodically assessed by timed manual searches with a dislodging aerosol. Vector infection was mainly determined by kDNA-PCR and blood meal sources were determined by enzyme-linked immunosorbent assay. RESULTS: In fluralaner-treated households, site infestation dropped from 100% at 0 MPT to 18–19% over the period 6–22 MPT while mean abundance plummeted from 5.5 to 0.6 triatomines per unit effort. In control households, infestation dropped similarly post-treatment. The overall prevalence of T. cruzi infection steadily decreased from 13.8% at 0–1 MPT (baseline) to 6.4% and subsequently 2.3% thereafter, while in domiciles, kitchens and storerooms it dropped from 17.4% to 4.7% and subsequently 3.3% thereafter. Most infected triatomines occurred in domiciles and had fed on humans. Infected-bug abundance plummeted after fluralaner treatment and remained marginal or nil thereafter. The human blood index of triatomines collected in domiciles, kitchens and storerooms highly significantly fell from 42.9% at baseline to 5.3–9.1% over the period 6–10 MPT, increasing to 36.8% at 22 MPT. Dog blood meals occurred before fluralaner administration only. The cat blood index increased from 9.9% at baseline to 57.9–72.7% over the period 6–10 MPT and dropped to 5.3% at 22 MPT, whereas chicken blood meals rose from 39.6% to 63.2–88.6%. CONCLUSION: Fluralaner severely impacted infestation- and transmission-related indices over nearly 2 years, causing evident effects at 1 MPT, and deserves larger efficacy trials. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13071-022-05343-2.
format Online
Article
Text
id pubmed-9277862
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-92778622022-07-14 Treatment of dogs with fluralaner reduced pyrethroid-resistant Triatoma infestans abundance, Trypanosoma cruzi infection and human-triatomine contact in the Argentine Chaco Gürtler, Ricardo Esteban Laiño, Mariano Alberto Alvedro, Alejandra Enriquez, Gustavo Fabián Macchiaverna, Natalia Paula Gaspe, María Sol Cardinal, Marta Victoria Parasit Vectors Research BACKGROUND: Triatomine elimination efforts and the interruption of domestic transmission of Trypanosoma cruzi are hampered by pyrethroid resistance. Fluralaner, a long-lasting ectoparasiticide administered to dogs, substantially reduced site infestation and abundance of pyrethroid-resistant Triatoma infestans Klug (Heteroptera: Reduviidae) in an ongoing 10-month trial in Castelli (Chaco Province, Argentina). We assessed the effects of fluralaner on vector infection with T. cruzi and blood meal sources stratified by ecotope and quantified its medium-term effects on site infestation and triatomine abundance. METHODS: We conducted a placebo-controlled, before-and-after efficacy trial of fluralaner in 28 infested sites over a 22-month period. All dogs received either an oral dose of fluralaner (treated group) or placebo (control group) at 0 month post-treatment [MPT]. Placebo-treated dogs were rescue-treated with fluralaner at 1 MPT, as were all eligible dogs at 7 MPT. Site-level infestation and abundance were periodically assessed by timed manual searches with a dislodging aerosol. Vector infection was mainly determined by kDNA-PCR and blood meal sources were determined by enzyme-linked immunosorbent assay. RESULTS: In fluralaner-treated households, site infestation dropped from 100% at 0 MPT to 18–19% over the period 6–22 MPT while mean abundance plummeted from 5.5 to 0.6 triatomines per unit effort. In control households, infestation dropped similarly post-treatment. The overall prevalence of T. cruzi infection steadily decreased from 13.8% at 0–1 MPT (baseline) to 6.4% and subsequently 2.3% thereafter, while in domiciles, kitchens and storerooms it dropped from 17.4% to 4.7% and subsequently 3.3% thereafter. Most infected triatomines occurred in domiciles and had fed on humans. Infected-bug abundance plummeted after fluralaner treatment and remained marginal or nil thereafter. The human blood index of triatomines collected in domiciles, kitchens and storerooms highly significantly fell from 42.9% at baseline to 5.3–9.1% over the period 6–10 MPT, increasing to 36.8% at 22 MPT. Dog blood meals occurred before fluralaner administration only. The cat blood index increased from 9.9% at baseline to 57.9–72.7% over the period 6–10 MPT and dropped to 5.3% at 22 MPT, whereas chicken blood meals rose from 39.6% to 63.2–88.6%. CONCLUSION: Fluralaner severely impacted infestation- and transmission-related indices over nearly 2 years, causing evident effects at 1 MPT, and deserves larger efficacy trials. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13071-022-05343-2. BioMed Central 2022-07-13 /pmc/articles/PMC9277862/ /pubmed/35831874 http://dx.doi.org/10.1186/s13071-022-05343-2 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Gürtler, Ricardo Esteban
Laiño, Mariano Alberto
Alvedro, Alejandra
Enriquez, Gustavo Fabián
Macchiaverna, Natalia Paula
Gaspe, María Sol
Cardinal, Marta Victoria
Treatment of dogs with fluralaner reduced pyrethroid-resistant Triatoma infestans abundance, Trypanosoma cruzi infection and human-triatomine contact in the Argentine Chaco
title Treatment of dogs with fluralaner reduced pyrethroid-resistant Triatoma infestans abundance, Trypanosoma cruzi infection and human-triatomine contact in the Argentine Chaco
title_full Treatment of dogs with fluralaner reduced pyrethroid-resistant Triatoma infestans abundance, Trypanosoma cruzi infection and human-triatomine contact in the Argentine Chaco
title_fullStr Treatment of dogs with fluralaner reduced pyrethroid-resistant Triatoma infestans abundance, Trypanosoma cruzi infection and human-triatomine contact in the Argentine Chaco
title_full_unstemmed Treatment of dogs with fluralaner reduced pyrethroid-resistant Triatoma infestans abundance, Trypanosoma cruzi infection and human-triatomine contact in the Argentine Chaco
title_short Treatment of dogs with fluralaner reduced pyrethroid-resistant Triatoma infestans abundance, Trypanosoma cruzi infection and human-triatomine contact in the Argentine Chaco
title_sort treatment of dogs with fluralaner reduced pyrethroid-resistant triatoma infestans abundance, trypanosoma cruzi infection and human-triatomine contact in the argentine chaco
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9277862/
https://www.ncbi.nlm.nih.gov/pubmed/35831874
http://dx.doi.org/10.1186/s13071-022-05343-2
work_keys_str_mv AT gurtlerricardoesteban treatmentofdogswithfluralanerreducedpyrethroidresistanttriatomainfestansabundancetrypanosomacruziinfectionandhumantriatominecontactintheargentinechaco
AT lainomarianoalberto treatmentofdogswithfluralanerreducedpyrethroidresistanttriatomainfestansabundancetrypanosomacruziinfectionandhumantriatominecontactintheargentinechaco
AT alvedroalejandra treatmentofdogswithfluralanerreducedpyrethroidresistanttriatomainfestansabundancetrypanosomacruziinfectionandhumantriatominecontactintheargentinechaco
AT enriquezgustavofabian treatmentofdogswithfluralanerreducedpyrethroidresistanttriatomainfestansabundancetrypanosomacruziinfectionandhumantriatominecontactintheargentinechaco
AT macchiavernanataliapaula treatmentofdogswithfluralanerreducedpyrethroidresistanttriatomainfestansabundancetrypanosomacruziinfectionandhumantriatominecontactintheargentinechaco
AT gaspemariasol treatmentofdogswithfluralanerreducedpyrethroidresistanttriatomainfestansabundancetrypanosomacruziinfectionandhumantriatominecontactintheargentinechaco
AT cardinalmartavictoria treatmentofdogswithfluralanerreducedpyrethroidresistanttriatomainfestansabundancetrypanosomacruziinfectionandhumantriatominecontactintheargentinechaco